COMPANY PROFILE

Vertex Pharmaceuticals

Explore full profile

Focused on the discovery and development of small molecule drugs for the treatment of serious diseases

Boston, United StatesFounded 1989Biotech & Life Sciences

Valuation $125B Market cap · 2026

Revenue $13B Latest reported FY

EBITDA $5.83B Latest reported FY

About Vertex Pharmaceuticals

Vertex Pharmaceuticals, accessible via vrtx.com, is a global biotechnology company dedicated to developing transformative medicines for serious diseases. The company focuses on scientific innovation and takes calculated risks to address unmet medical needs. Vertex primarily serves patients with severe and life-threatening conditions, such as cystic fibrosis, by creating groundbreaking treatments that can significantly improve their quality of life.

Operating in the biotechnology and pharmaceutical market, Vertex's business model revolves around extensive research and development (R&D) to discover and develop new drugs. The company invests heavily in scientific research, often collaborating with other biotech firms, like Arbor Biotechnologies, to advance its therapeutic pipeline. For instance, Vertex and Arbor Biotechnologies have partnered to develop novel ex vivo engineered cell therapies, which involve modifying cells outside the body to treat diseases.

Vertex generates revenue through the commercialization of its approved drugs. One of its key products is ivacaftor, a medication for cystic fibrosis, which has shown promising results in Phase 3 clinical trials. The company also earns income from licensing agreements and partnerships with other biotech firms, which help to expand its research capabilities and product offerings.

The company is led by a team of experienced executives, including Stuart A. Arbuckle, the newly appointed Chief Operating Officer. Vertex's headquarters are located in Boston, Massachusetts, but it operates on a global scale, reflecting its commitment to addressing serious health issues worldwide.

In summary, Vertex Pharmaceuticals is a pioneering biotech firm that focuses on developing innovative treatments for severe diseases, primarily through rigorous R&D and strategic partnerships. Its business model is centered on bringing new, effective drugs to market, thereby generating revenue and improving patient outcomes.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 1989
Headquarters: Boston, United States
Listing: IPO 1991
Employees: 6,448
Open positions: 185
Dealroom signal: 82.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Genetics and genomics, Molecular Biology, Chronic Disease, Crispr, Gene Therapy, Biotech and Pharma
Client focus: b2c
Investment activity: 10 companies, latest Jul 2026
Capital deployed: $396M
Preferred round: SERIES B
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

9 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
OtherOther financing	Jun 2026	$0	—	Wealthfront	↗
POST IPO EQUITY✓Other financing	Dec 2025	$0	—	GF Fund Management	↗

Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$13B	+9.9%	$5.8B	44.2%	$4.3B	32.7%	$4B
2025	$12B	+8.9%	$5.2B	43.7%	$4B	32.9%	$4B
2024	$11B	+11.7%	$5.1B	46.4%	−$536M	-4.9%	$3.6B
2023	$9.9B	+10.5%	$5.1B	51.5%			$3.2B
2022	$8.9B	+17.9%	$4.3B	48.7%
2021	$7.6B	+22.1%	$2.8B	36.8%
2020	$6.2B	—	$3.2B	51.4%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Vertex Pharmaceuticals website traffic

Latest recorded traffic for Vertex Pharmaceuticals is 200K monthly website visits, up 81.8% over the last three months. Vertex Pharmaceuticals's team grew 39.1% over the past year.

Latest monthly visits200K 3-month web change+81.8% 1-year team growth+39.1%

Monthly website visitsApr 2016–Mar 2021

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SBSNIPR BiomeSNIPR Biome is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future	Copenhagen, Denmark	Operational	46	$109M	$250M
VEVectorialisNon-viral nanoparticle technology for nucleic acid delivery	Milan, Italy	Operational
GEGENOLIFEPrecision medicine through specialized DNA and genome studies	Guadalajara, Mexico	Operational
GLGluGeneAdeno-associated virus gene therapy products for incurable diseases, engineered to address the intrinsic problems of viral vectors	Daejeon, South Korea	Operational
MTMerlin TherapeuticsTherapeutic solutions for Neurofibromatosis type 2 (NF2), a rare genetic disorder causing the growth of multiple tumors	Tempe, United States	Operational
RNRNAleadA versatile RNA delivery platform for gene and cell therapies, supporting cell reprogramming, CRISPR Cas9 delivery, and base editing.	Toulouse, France	Operational
FLFluorionExpert solutions and a scientific community for cell and gene therapy, accelerating assay development and clinical trial preparation	—	Operational
AIApriligen, Inc.A clinical-stage gene therapy platform using a lentiviral vector to treat rare pediatric diseases like Diamond Blackfan Anemia	—	Operational